Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia (BLAST)

Open-label single-arm study: 116 adults with B-cell precursor ALL in hematologic CR with MRD ≥10^-3 received blinatumomab for up to 4 cycles. 88 of 113 evaluable patients (78%) achieved a complete MRD response after 1 cycle. In 110 Ph-negative patients, 18-month RFS was 54%; median OS 36.5 months. Complete MRD responders had longer RFS (23.6 vs 5.7 months, P=0.002) and OS (38.9 vs 12.5 months, P=0.002) than nonresponders. This trial supported the March 29, 2018 FDA approval. Single-arm (level 2); the approval itself is filed as regulatory level 1.

BloodPubMed 29358182